Search Results
Highly Anticipated Data from the SOLO-1 Trial
SOLO-1: practice changing data on olaparib for ovarian cancer
Comment on SOLO1 trial
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer
SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib
Results from phIII SOLO1 trial in BRCAm ovarian cancer
Impact of SOLO-1 on Advanced Ovarian Cancer Management
SOLO-1 and PARP Inhibitors in Ovarian Cancer
Comment on SOLO1 for advanced ovarian cancer
The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer
Olaparib Maintenance for Recurrent Ovarian Cancer
SOLO-1: practice changing results for advanced ovarian cancer